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Abstract
Introduction and Objective: Specimen morcellation during laparoscopic radical nephrectomy (LRN) for renal
cell carcinoma (RCC) is controversial. We seek to evaluate the safety and efficacy of specimen morcellation and
LRN for treatment of presumed malignant renal lesions.
Methods: We retrospectively reviewed all patients who underwent LRN at three academic institutions from 1996
to 2007. One hundred eighty-eight patients underwent specimen morcellation after LRN for enhancing solid or
cystic renal masses.
Results: LRN was successfully performed on all the patients. Patient age ranged from 36 to 94. One hundred
sixty-seven patients were in clinical stage T1, 19 patients T2, and unknown in two. The specimen was manually
morcellated within a Cook Lap Sac or Endocatch II bag under laparoscopic or direct observation. On histological
review of morcellated specimens, 165 patients were confirmed to have RCC, 17 had an oncocytoma, and 2 had
benign cysts. At least 13 patients with RCC were pathologically upgraded to stage T3. Mean operative time was
225 minutes (range 94–650). Mean hospital stay was 2.5 days (range 1–8). In patients with RCC, 11 developed
recurrent disease with mean follow-up of 21 months (range 0.3–111). In one patient, a port site recurrence
occurred in concert with renal fossa and lymph node metastases.
Conclusions: Intracorporeal mechanical morcellation after LRN appears to be safe and effective in clinical stage
T1 and T2 RCC. This supports the use of morcellation as an alternative for intact specimen removal in properly
selected patients.
Introduction
Morcellation in conjunction with laparoscopic rad-ical nephrectomy (LRN) has been an area of contro-
versy since Clayman et al1 described the initial LRN with
morcellation in 1991. It makes sense to use the existing ports to
morcellate and extract the specimen and preserve the integ-
rity of a minimally invasive laparoscopic operation. Critics
counter that morcellation does not allow for adequate tumor
staging and therefore may impact the ability to enroll patients
in clinical chemotherapy trials. There also is a concern over
intraabdominal, port site, and extraction site tumor seeding.
In this multiinstitutional study, we sought to evaluate the
safety and efficacy of specimen morcellation in conjunction
with LRN for presumed renal cell carcinoma (RCC).
Materials and Methods
Records of all patients who underwent LRN from 1996 to
2007 were retrospectively reviewed at three academic urology
departments. All procedures using manual morcellation of
kidneys suspected of containing clinical stage T1 or T2, N0
RCC were included in the analysis. Postoperative follow-up
included physical exam, routine laboratory studies, as well as
axial imaging with computed tomography or magnetic reso-
nance imaging to evaluate for complications and recurrent or
metastatic disease.
The specimen entrapment and morcellation technique
varied between institutions but universally involved the basic
principles of performing morcellation under direct and=or
laparoscopic vision; this includes extensive draping around
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the port site through which the morcellated specimen is de-
livered to prevent tumor spill and dissemination. The tech-
niques of specimen entrapment and morcellation utilized at
Northwestern University have been previously described.2 At
the University of California, Irvine, morcellation is performed
by placing the specimen into a LapSac (Cook Urological,
Spencer, IN) that is delivered through the caudal most port
site that has been enlarged to 20 mm. This is followed by a
triple draping of the surgical field around the port site. The
neck of the LapSac is covered by a sterile adhesive drape, a
fenestrated absorbent towel, and a nephrostomy drape. The
neck of the LapSac is passed through a hole in each of these
drapes. These precautions are taken to help prevent potential
wound contamination by any spilled tumor cells. The tumor is
then manually morcellated using a Sopher gynecological ring
forceps that has 1445 mm reinforced jaws. After completion
of morcellation, the surgeon and all other members of the
surgical team who participated during morcellation regown
and reglove.
The University of Michigan has utilized both an imper-
meable nylon sac (i.e., LapSac) with intracorporeal morcella-
tion and later adopted the technique described by Landman
et al,3 which entails placing the specimen in a self-opening
plastic sac (Endo Catch II; Autosuture, Norwalk, CT) and
lengthening a port site incision until the sac contents can be
seen (typically 2–4 cm, depending on patient’s body wall
thickness). Specimen morcellation is then performed under
direct observation above the abdominal wall. A fenestrated
drape is used to protect the port site from potential seeding.
Once the specimen has been extracted, the incision is irrigated
with 200 mL of sterile water after the surgical team regown
and reglove. Table 1 compares the variations in morcellation
technique among the three institutions.
Results
One hundred eighty-eight patients underwent LRN for
renal lesions suspicious for clinical stage T1 and T2, N0, M0
RCC. Seventy-four patients were female (40%) and 113 male
(60%). Mean age was 62.6 (range 24–94). Preoperative clinical
staging was T1N0M0 in 167 (89%) patients and T2N0M0 in 19
(10%). Clinical staging information was not available for two
patients (Table 2).
None of the cases required conversion to an open proce-
dure. Morcellation of renal tumor specimens occurred with-
out spillage or perforation of the LapSac or EndoCatch II sack.
Morcellation time was not assessed. Mean operating time was
225 minutes (range 94–650 minutes). No gross tumor spillage
occurred and no perforation of entrapment sacks was noted
during morcellation.
Average tumor size was 4.9 cm (range 1.5–16). Histologic
review of morcellated specimens revealed that 165 (87%)
patients had RCC, 17 (9%) had oncocytomas, 2 (1%) had
benign cysts, and 1 had both transitional cell carcinoma and
RCC. Thirteen (7%) patients had a pathologic upgrade to pT3
(Table 2).
Thirty patients (16%) experienced complications. Thirty-
eight complications were reported overall (Table 3): 4 cardiac,
5 respiratory=thromboembolic events, 8 gastrointestinal,
14 renal=genitourinary, 2 neurologic, 4 postoperative bleeds,
and 1 death. One extraction site wound infection occurred.
One extraction site incisional hernia occurred. Mean hospital
stay was 2.5 days (SD 1.6 days). Mean follow-up was 21.3
months (range 0–111). Out of 11 recurrences (5.8%), 10 were
pulmonary or visceral recurrences and 1 in the tumor bed
(Table 4). In one patient, a port site recurrence occurred in
concert with renal fossa recurrence and lymph node metas-
tases. There were no isolated port site recurrences. No cancer-
related deaths occurred during follow-up period.
Discussion
Laparoscopic nephrectomy was originally described by
Clayman et al1 in 1991. It was predicated on specimen mor-
cellation to minimize employment of more invasive enlarged
incisions on the abdomen. To that end, the LapSac and an
electronic morcellator were developed. The latter is no longer
commercially available. Since then laparoscopic radical or
total nephrectomy has been widely accepted as an oncologi-
cally sound and safe technique.4–11 Advantages in analgesic
use and recovery compared with open nephrectomy have
been documented.6,8 Although the initial report of LRN de-
scribed entrapment and morcellation of the kidney and tumor
specimen, morcellation has not become a widely accepted
practice.
From a technical standpoint, morcellation can be per-
formed safely without increased risk of tumor spillage. First,
the LapSac has been shown to be impermeable to tumor
spillage. Urban and colleagues found no diffusion of bovine
serum albumin, indigo carmine, or mouse bladder tumor cells
into dialysate when LapSacs were used as a dialysis mem-
brane.12 Deployment of the LapSac can be simply accom-
Table 1. Morcellation Techniques Used at Respective Institutions
Institution
University of
California, Irvine University of Michigan Northwestern University
Entrapment=extraction
port site
Most caudal Most caudal Most caudal
Morcellation port site Most caudal Most caudal Umbilical




20 mm 20–40 mm 20 mm
Draping Clear plastic adhesive drape
fenestrated absorbent towel
nephrostomy drape
Fenestrated drape Sterile towels
Morcellation instrument Sopher clamp Sopher clamp Ring forceps
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plished as described by User and Nadler.2 With this tech-
nique, a LapSac is secured to the frame of an Endocatch II
device after the original specimen sack is removed. The
LapSac is then rolled tightly and the compressed frame and
sack are drawn back into the cannula of the device. The device
then can be redeployed as usual. The University of Michigan
uses the morcellation technique described by Landman et al.3
Specimens are morcellated within an Endocatch II entrap-
ment sack, which when compared with a LapSac is more
flimsy. To ensure against tumor spillage, the authors modified
their technique to widen the extraction incision to 3 cm and to
only grasp and morcellate tissue that is protruding outside
(i.e., extracorporeal) the wound. Endocatch II sack integrity
was maintained in all cases, and no trocar site or local recur-
rences were noted in follow-up.3 Proper technique is required
in all cases with morcellation under direct and=or laparo-
scopic vision to prevent perforation of the sack, as neither sack
is immune to perforation. Lastly adequate draping must be
undertaken to prevent wound contamination, and all instru-
ments, gowns, and gloves are changed at the end of morcel-
lation before proceeding with the remainder of the surgery.13
Advantages in postoperative analgesic usage and con-
valescence are shown to favor laparoscopic over open
nephrectomies.7,14,15 Nadler compared 33 patients who were
prospectively enrolled and assigned in alternating fashion to
receive hand-assisted, transperitoneal with morcellation or
retroperitoneal laparoscopic nephrectomy. Intact specimen
removal was performed in the hand-assisted and retroperi-
toneal groups. Patients who underwent morcellation had
shorter hospital stays and time to normal daily activity.16
Camargo et al17 also demonstrated decreased narcotic re-
quirement favoring morcellation versus intact specimen re-
moval. Two studies that compared intact versus morcellated
specimen removal showed no difference in postoperative
status, but these studies were not randomized and had small
numbers11 or did not compare similar populations.18
Critics also cite port site and peritoneal seeding as reasons
against performing morcellation. However, only several case
reports have shown this. Barrett et al19 described a solitary
port site recurrence at 25 months in a patient with an ad-
vanced and large specimen (pT3N0M0 grade 4, 862 gm). Two
cases were reported by Castilho and associates.20,21 Both pa-
tients had pT1N0 grade 2 RCC that presented 5 and 12 months
after LRN. Both patients presented with abdominal masses
under the trocar sites and ascites. Risk factors cited as possibly
contributing to recurrence included not using a LapSac spe-
cifically designed for morcellation, presence of ascites at time
of nephrectomy, and unrecognized microperforations in the
sack. Recent reviews on tumor seeding and port site metas-
tases in urologic laparoscopy have shown this to be rare in the
context of nephrectomy and morcellation done for presumed
RCC.22–25 In Micali’s survey of over 2600 laparoscopic radical
nephrectomies, no tumor seeding was noted.22 Certainly,
these numbers compare favorably with that of incisional scar
metastases after open radical nephrectomy for RCC (0.4%).24
In our multiinstitutional study, one port site metastases de-
veloped in concert with renal fossa and lymph node recur-
rence. Ten out of the 11 recurrences were either pulmonary or
visceral in location. This is also consistent with reported
data.4,5,7,8,22,23
Concern remains, however, regarding loss of patho-
logic staging with specimen morcellation.26 Preoperative
Table 2. Patient Characteristics
and Select Perioperative Outcomes
n 188
Mean patient age, year (SD) 62.6 (13.5)
Number of females (%) 74 (39%)
Mean tumor size, cm (SD) 4.9 (2.2)













Clear cell RCC 137 (73%)
Papillary RCC 12 (6%)
Chromophobe RCC 13 (7%)




Benign cyst 2 (1%)
NA 3 (2%)
Tumor recurrence (%) 11 (5.8%)
Mean time to recurrence, month 19.4
Recurrence site
Morcellation port site 1
Other port site 0
Renal fossa 1
Pulmonary=visceral 10
Cancer related deaths 0
Mean follow-up time, month (SD) 21.3 (22.0)
Mean EBL, mL (SD) 200 (315)
OR time, minute (SD) 225 (80)
Mean length of stay, days (SD) 2.5 (1.6)
aPatient had both clear cell and papillary RCC.
bPatient had both papillary RCC and TCC.
NA¼not available; SD¼ standard deviation; RCC¼ renal cell











Postoperative bleed 4 (11%)
Death 1 (2%)
Total no. of complications 38 (100%)
MI¼myocardial infarction; PE¼pulmonary embolism; DVT¼
deep vein thrombosis.
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staging based on axial radiographic imaging (i.e., computed
tomography or magnetic resonance imaging) is accurate but
may under- or overstage tumors in 5% to 35% of cases.27
Distinguishing between T2 and T3a tumors may be especially
problematic because of tumor size and lack of sensitive ra-
diographic findings.28 Grade and histologic type can be reli-
ably and accurately identified in morcellated specimens.27,29
Various methods of specimen preparation to enhance accu-
racy of pathologic evaluation after morcellation have been
reported and demonstrate that accurate pathologic staging is
possible.29 Indian Ink staining of the specimen after entrap-
ment but before morcellation allows pathologic determina-
tion of surgical margin status.30 Needle core biopsy of intact
specimen before morcellation is accurate in confirming his-
tologic diagnosis.31 Pathologic staging may also be success-
fully accomplished when morcellation is performed through a
slightly extended extraction incision allowing for removal of
larger fragments.3 Additional prognostic factors such as mi-
crovascular invasion can be assessed in morcellated speci-
mens, but renal sinus fat invasion may not be reliably
determined.9,29,32 Renal sinus fat invasion, however, is often
associated with other negative prognostic indicators (e.g.,
perirenal fat invasion, lymph node metastases) that may be
reliably determined.29,33,34 Further, systematic models of
sampling morcellated specimens have been developed to
determine the amount of tissue to be examined to arrive at the
diagnosis with a given degree of certainty.35
No clear evidence exists that pathologic staging informa-
tion lost because of specimen morcellation affects clinical
follow-up or survival.4,5,7,8,13,14,36 Specifically, recurrence-free
survival, disease-free survival, and overall survival do not
appear to be different between open and laparoscopic ne-
phrectomy with morcellation.7–9,14 Reports of pathologic up-
staging for clinical T1 RCC and its impact on prognosis have
been conflicting at best.36,37 Roberts found that up to 31% of
the patients diagnosed with clinical T1 RCC were upstaged to
pathologic T3a. However, recurrence-free survival did not
differ between patients with pT1 and pT3a (in this study,
defined as microscopic perinephric fat invasion) RCC.36 This
study implies that current tumor nodes metastasis staging for
pT3a tumors with microscopic perinephric fat invasion may
not always correlate with prognosis and absence of pathologic
staging after morcellation may be, in some cases, more an
academic concern rather than a clinical one. Svatek and col-
leagues37 found that 9% of the clinical T1 RCC were upstaged
pT3a (excluding adrenal involvement). Unlike the Roberts’
study, patients with clinical T1 tumors that were pathologi-
cally upstaged exhibited higher probability of disease recur-
rence and cancer-specific death.37 Finally, lack of durable and
standardized adjuvant therapy also diminishes the impact of
potential pathologic staging information lost with specimen
morcellation. Even with advent of targeted antivascular
agents in treatment of metastatic RCC, these agents are still
under investigation for use in the adjuvant setting.38 Cohen
and colleagues39 argue, however, that it is precisely for this
reason patients should undergo intact specimen extraction to
identify potential candidates to enroll in adjuvant therapy
trials.
In our present multiinstitutional series, morcellation
technique–related complications were rare, and the subse-
quent rare occurrence of metastatic disease could not be
ascribed to morcellation. Operating time and length of hos-
pitalization are also consistent with previously published
LRN series.4,5,7,8 Thirty patients overall experienced compli-
cations (16%) that are consistent with reported laparoscopic
nephrectomy series.4–6,8,13 One perioperative death occurred.
This patient also had cardiopulmonary complications after
a relatively lengthy case (365 minutes) during a prolonged
hospitalization of 14 days. Interestingly, only one extraction
site incisional hernia was reported (0.5%), despite upward
force applied to the extraction site during the actual process of
morcellation. This compares favorably to intact specimen
extraction after laparoscopic nephrectomy that is associated
with incisional hernias in up to 36% with a hand-assisted
approach16 and also reported rates of trocar site hernias
(0.02%–5%).40 Elashry et al41 found a 17% rate of incisional
hernias when the intact specimen was extracted from a lower
flank port-connecting incision.
Weaknesses of this study are the lack of prospective ran-
domized comparison of intact versus morcellated specimen
removal. Further, patient characteristics (e.g., body mass in-
dex, comorbidities) were not evaluated; these characteristics
certainly can influence outcomes. Clinical staging (e.g., nodal
status, tumor size) and pathologic information were missing
for some patients. Lastly, a comprehensive study evaluating
the benefits of morcellation should also include functional
















78 M T1b No 6 – Clear cell 2 18.8 Lung
39 F T1b Yes 5 – Clear cell 4 1.5 Lung
51 M T1b No 5 – Clear cell 2 37.1 Lung
54 M T1b No 6.8 – Clear cell 4 42.7 Brain
75 F T1a No 2.5 – Clear cell 3 7.5 Bone
61 M T1b No 5.5 – Clear cell 3 45.7 Lung
76 M T1a No 3.5 – Clear cell 2 29.5 Larynx
61 F T2 No 8 T3a Clear cell 4 6.3 Lung
40 M T2 No 7.3 T3a Clear cell 3 7.3 Renal fossa, port site,
lymph node
65 F T2 No 8 T3a Clear cell 3 10.9 Contralateral kidney
80 F T2 No 13 T3a Clear cell 4 5.7 Abdomen and bone
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outcomes (i.e., postoperative pain scores, time to return to
normal activity) in addition to oncologic ones.
Conclusions
Morcellation is a safe method of specimen extraction after
laparoscopic total radical=total nephrectomy. Our data sup-
port that there is equivalent survival in the morcellated pa-
tient cohort compared with open nephrectomy. Concerns for
inaccurate pathologic staging are offset by similar survival
seen between open and laparoscopic nephrectomy with
morcellation and the documented ability to obtain accurate
histology, assess for lymphovascular invasion, and to still
stage the disease given the size of morcellated pieces. It would
appear that only in those cases that require very specific in-
formation about pathologic staging (e.g., research protocols—
ASSURE, S-TRAC, SORCE; qualification for adjuvant thera-
pies, determining more intensive surveillance schedules,
possibility of upper tract urothelial carcinoma) should mor-
cellation not be performed.
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EBL¼ estimated blood loss
LRN¼ laparoscopic radical nephrectomy
NA¼not available
RCC¼ renal cell carcinoma
SD¼ standard deviation
TCC¼ transitional cell carcinoma
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